The use of androgen deprivation therapy (ADT) and chemotherapeutic agents in new zealand men with prostate cancer

Journal of Cancer

Volumn 5, Issue 3, 2014, Pages 214-220

  Lawrenson, Ross ^a   Obertová, Zuzana ^a   Brown, Charis ^a   Fong, Peter ^b   Tyrie, Leanne ^c   Scott, Nina ^d   Holmes, Michael ^c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b AUCKLAND DISTRICT HEALTH BOARD   (New Zealand)

^c WAIKATO HOSPITAL   (New Zealand)

^d Waikato District Health Board   (New Zealand)

Author keywords

Anti androgens; Chemotherapy; LHRH analogues; Orchidectomy; Prostate cancer

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT; BICALUTAMIDE; CYPROTERONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUTAMIDE; GONADORELIN; GOSERELIN; LEUPRORELIN; MITOXANTRONE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER REGISTRY; CANCER SURGERY; CONTROLLED STUDY; ETHNICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEW ZEALAND; ORCHIECTOMY; PRESCRIPTION; PROSTATE CANCER; VERY ELDERLY;

EID: 84896950502     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.8152     Document Type: Article

References (19)

1. Ministry of Health. New Registrations and Deaths 2006: Revised edition. Wellington: Ministry of Health; 2010.
2. Johansson JE, Holmberg L, Johansson S, et al. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 1997; 277: 467-71.
3. Obertová Z, Hodgson F, Holmes M, et al. Characteristics of men diagnosed with prostate cancer in New Zealand general practice. NZ Med J 2013; 126 (1387).
4. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst 2006; 98: 839-45.
5. National Institute for Health and Clinical Excellence (NICE). Prostate cancer - diagnosis and treatment. Clinical guideline 58. London: NICE; 2008.
6. Robson B, Harris R (eds). Hauora: Maori standards of health IV. A study of the years 2000-2005. Wellington: Te Ropu Rangahau Hauora a Eru Pomare; 2007.
7. Obertová Z, Scott N, Brown C, et al. Survival disparities between Maori and non-Maori men with non-localised prostate cancer in New Zealand. BJU Int Suppl. 2013; 112 (1): 14.
8. Hussain S, Gunnell D, Donovan J, et al. Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004. BJU Int 2008; 101: 547-55.
9. Pagliarulo V, Bracarda S, Eisenberger MA, et al. Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol 2012; 61: 11-25.
10. Australian Cancer Network Management of Metastatic Prostate Cancer Working Party. Clinical Practice Guidelines for the Management of Locally Advanced and Metastatic Prostate Cancer. Sydney: Cancer Council Australia and Australian Cancer Network; 2010.
11. Onukwugha E, Mullins CD, Hsu VD, et al. Effect of Urologists and Medical Oncologists on Treatment of Elderly Men With Stage IV Prostate Cancer. Urology 2011; 77: 1088-96.
12. Morrison BF, Aiken WD, Reid ME. Impact of the National Health Fund policy on hormone treatment for prostate cancer in Jamaica. Rev Panam Salud Publica 2011; 29: 404-8.
13. Grundmark B, Garmo H, Zethelius B, et al. Anti-androgen prescribing patterns, patient treatment adherence and influencing factors; results from the nationwide PCBaSe Sweden. Eur J Clin Pharmacol 2012; 68: 1619-30.
14. Akaza H. Future prospects for luteinizing hormone-releasing hormone analogues in prostate cancer treatment. Pharmacology 2010; 85: 110-20.
15. Akaza H, Hinotsu S, Cooperberg MR, et al. Sixth joint meeting of J-CaP and CaPSURE-A multinational perspective on prostate cancer management and patient outcomes. Jpn J Clin Oncol 2013; 43: 756-66.
16. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 2003; 95: 981-9.
17. Kuykendal AR, Hendrix LH, Salloum RG, et al. Guideline-discordant androgen deprivation therapy in localized prostate cancer: patterns of use in the medicare population and cost implications. Ann Oncol 2013; 24: 1338-43.
18. Dinan MA, Robinson TJ, Zagar TM, et al. Changes in initial treatment for prostate cancer among Medicare beneficiaries, 1999-2007. Int J Radiation Oncol Biol Phys 2012; 22: 781-6.
19. Ministry of Health. Treatment: Report of the Treatment Expert Working Group to the New Zealand Cancer Control Steering Group. Wellington: Ministry of Health; 2003.